Rheumatology - European Medical Journal

Continue

Rheumatology

Filter
23 Sep 2016

EFIC Symposium: New Therapeutic Strategies to Combat Joint Pain

Dubrovnik, September 23, 2016 – Joint pain continues to be one of the main reasons for persisting disablement. One explanation, among others, is that…
22 Sep 2016

EFIC Symposium: Chronic Pain Following Joint Surgery – Experts Call for New Approaches

Dubrovnik, September 22, 2016 – Many patients are disappointed and dissatisfied when they find they are still experiencing pain in the months and years…
22 Sep 2016

EFIC Symposium: Myths and Facts About Joint Pain

Dubrovnik, September 21, 2016 – A lot of incorrect assumptions about joint pain are in circulation. “The sometimes overly pessimistic misconceptions can…
7 Sep 2016

Myocardial Nuclear Imaging: Minimizing the Dose – Preserving the Diagnostic Value

Vienna, September 6, 2016 – Cardiac scintigraphy plays an important role in the evaluation of patients with a suspicion or known coronary artery disease…
EMJ
18 Jul 2016

Hip Surgery May Not Be Best Choice

EVIDENCE from a study carried out in the USA shows that arthroscopic hip surgery might not always be a suitable option for people with osteoarthritis…
EMJ
18 Jul 2016

Adalimumab Drug Suppresses Inflammation in Rheumatoid Arthritis Patients

DISCOVERY of a new function in a widely used anti-inflammatory drug could offer new insight into the divergent efficacies of different medications which…
17 Jun 2016

New Data Presented at the Annual European Congress of Rheumatology (EULAR 2016) Demonstrate Safety and Efficacy of Biogen’s Anti-TNF Biosimilars Portfolio

June 09, 2016 07:08 AM Eastern Daylight Time ZUG, Switzerland–(BUSINESS WIRE)–Data demonstrating long-term comparable efficacy, safety and immunogenicity…
10 Jun 2016

New Data Demonstrates Sandoz’ Etanercept and Rituximab Biosimilar Candidates Bioequivalent to Originator Products

Holzkirchen, June 9 2016 – Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced results from two key studies…
We’ve noticed you’re accessing
from North/South America.